1. Home
  2. Our Firm
  3. News
  4. Guggenheim Securities Hires Analyst Eric Wasserstrom, Broadening Financial Services Coverage

Our Firm

September 03, 2014

Guggenheim Securities Hires Analyst Eric Wasserstrom, Broadening Financial Services Coverage

Growing team includes specialists in both equity research and policy analysis

NEW YORK – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, today announced the hiring of veteran equity analyst Eric Wasserstrom as a managing director and senior equity analyst.

Mr. Wasserstrom will begin work in November in New York, covering universal banks, broker-dealers and specialty finance firms. He will join the financial services research team that includes David Darst (regional banks and payments), Bijan Moazami (property/casualty insurance), Taylor Brodarick (community banks) and Rahul Agarwal (business development companies).

"Eric's comprehensive grasp of the financial services sector is informed by long experience in the industry, including a stint as a banking regulator," said Dante Ferrarie, Senior Managing Director at Guggenheim Securities. "The equity research team he joins is complemented by the financial services policy research insights of Jaret Seiberg in Washington, D.C."

Mr. Wasserstrom for the last two years has been a managing director and senior analyst at SunTrust Robinson Humphrey in New York, heading research in the financial institutions sector. Earlier, he worked for three years in investment management and for nine years as an analyst with UBS Securities in New York. He began his career with two years as a bank examiner with the Federal Reserve Bank of New York. Mr. Wasserstrom also has been ranked seven times in Institutional Investor's "All-America Research Team."

He graduated with a B.A. in History, summa cum laude and Phi Beta Kappa, from Tufts University.

Guggenheim Securities' research capabilities have been expanding in other key sectors besides financial services, including healthcare and technology/media/telecom. For example, Charles "Tony" Butler joined Guggenheim Securities in August as a managing director and senior equity analyst, covering biotech/biopharma.


About Guggenheim Partners

Guggenheim Partners is a global investment and advisory firm with more than $210 billion in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With over 2,500 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity.



November 09, 2020

Guggenheim Securities Hires David Levin to Expand Equity Capital Markets

NEW YORK, NY –  Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that David Levin will join the firm as a Senior Managing Director in Equity Capital Markets, focusing on providing clients with equity and equity-linked financing solutions through the public and alternative equity capital markets.

Read More

October 22, 2020

Guggenheim Securities Hires Joe Niemiec to Expand Middle Market Investment Banking Practice

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Joe Niemiec has joined the firm as a Senior Managing Director to expand its middle market investment banking coverage and to focus on advising companies in the services and industrials sectors.

Read More

October 05, 2020

Debjit Chattopadhyay Joins Guggenheim Securities as Senior Biotech Analyst

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Debjit Chattopadhyay will join the firm in December as a Managing Director and Senior Biotech Analyst as part of the Healthcare Equity Research team. Dr. Chattopadhyay’s research focus will be gene therapy and rare diseases.

Read More



© 2020 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and Innovative Solutions. Enduring Values. are registered trademarks of Guggenheim Capital, LLC.